Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04532567 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects
A Phase 1 study, sponsored by Lakefront Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04532567: Completed Phase 1 study, sponsored by Lakefront Biotherapeutics.
NCT04532567 is a Phase 1 study that has completed, run by Lakefront Biotherapeutics. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04532567, a Phase 1 study, has completed, sponsored by Lakefront Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this research study is to assess the safety and tolerability of GLPG1205 in single and multiple oral doses in healthy male Caucasian and Japanese subjects. This study will also assess the pharmacokinetics (PK) across different doses of GLPG1205. PK will look at how the study drug is absorbed, broken down, and eliminated by your body.
Interventions
- DRUG Placebo
- DRUG GLPG1205
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-08-18 |
| Est. Completion | 2020-12-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04532567
The ClinicalTrials.gov registry entry for NCT04532567 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lakefront Biotherapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04532567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04532567 about?
NCT04532567 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects". The purpose of this research study is to assess the safety and tolerability of GLPG1205 in single and multiple oral doses in healthy male Caucasian and Japanese subjects. This study will also assess the pharmacokinetics (PK) across different doses of GLPG1205. PK will look at how the study drug is a...
What is the current status of trial NCT04532567?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2020-08-18. Estimated completion is 2020-12-10.
What interventions are being tested in trial NCT04532567?
The interventions under investigation include: Placebo (DRUG), GLPG1205 (DRUG).
Who is sponsoring clinical trial NCT04532567?
This trial is sponsored by Lakefront Biotherapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.